Retrophin Reports Third Quarter 2015 Financial Results

Go back to Retrophin Reports Third Quarter 2015 Financial Results

Retrophin (RTRX) PT Trimmed to $44 at Leerink Partners Post Q3, 'Outperform' Maintained

November 4, 2015 6:54 AM EST

Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating but lowered his price target on Retrophin (NASDAQ: RTRX) to $44.00 (from $48.00) following Q3 results which beat on the top line. They note patient indemnification efforts are in focus.

Schwartz commented, "RTRX reported 3Q... More